These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Abnormalities of the genital tract following stilbestrol exposure in utero.
    Author: Kurman RJ.
    Journal: Recent Results Cancer Res; 1979; 66():161-74. PubMed ID: 373028.
    Abstract:
    9 figures and 5 tables elucidate this review of abnormal findings in female genital tracts of women exposed in utero to diethylstilbestrol (DES). Benign anomalies, other than clear-cell adenocarcinoma, associated with DES exposure include cervical or vaginal ridges and ectopic benign glandular epithelium in the vagina (adenosis) and cervix (ectropion). Of 144 women registered with the Registry of Clear-Cell Adenocarcinoma of the Genital Tract in Young Females, 78% were exposed to DES or some unknown medication for control of bleeding. Survival varies with stage of tumor, ranging from 83% in Stage I vaginal tumors to 20% in Stage III in IV. Survival of patients with cervical tumors showed a similar pattern, ranging from 95% at Stage I to 33% in the latter stages. The prevalence of benign abnormalities associated with in utero exposure to DES was (n=110 subjects) 35% for vaginal adenosis, 85% for cervical erosion, and 22% for ridges compared with 1%, 38%, and 0%, respectively, among 82 control subjects. The finding of extensive areas of cervical ectropion and vaginal adenosis associated with squamous metaphasia has led to the conclusion that one of the basic abnormalities of DES exposure is an aberrant location of the cervical transformation zone. As with carcinoma, a relationship between benign lesions and DES dosage could not be established. DES screening should begin at age 14 years in young women; at the present time, it seems unnecessary to screen young men exposed to DES in utero.
    [Abstract] [Full Text] [Related] [New Search]